Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.

Lan, Shao-Huan; Lai, Chih-Cheng; Chang, Shen-Peng; Lu, Li-Chin; Hung, Shun-Hsing; Lin, Wei-Ting

Lan, Shao-Huan; Lai, Chih-Cheng; Chang, Shen-Peng; Lu, Li-Chin; Hung, Shun-Hsing; Lin, Wei-Ting.

Afiliação

Lan SH; School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian, Fujian, China.
Lai CC; Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan.
Chang SP; Yijia Pharmacy, Tainan, Taiwan.
Lu LC; School of Management, Putian University, Putian, Fujian, China.
Hung SH; Division of Urology, Department of Surgery, Chi-Mei Hospital, Tainan, Taiwan.
Lin WT; Department of Orthopedic, Chi Mei Medical Center, Tainan, Taiwan.

Expert Rev Clin Pharmacol ; 15(6): 759-766, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35579014

Assuntos

Tratamento Farmacológico da COVID-19; Amidas/efeitos adversos; Humanos; Pirazinas/efeitos adversos; Ensaios Clínicos Controlados Aleatórios como Assunto

Palavras-chave

COVID-19; SARS-CoV-2; favipiravir; intensive care unit; mechanical ventilation; mortality; virological eradication

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Revista: Expert Rev Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google